Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update 30 April
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis 30 April
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call 23 April
